After reporting a green session on Tuesday, the stock price of Plandai Biotechnology Inc (OTCMKTS:PLPL) is once again moving south on the chart. Yesterday, the stock declined more than 3% to close the trading session at $0.125. The company recently confirmed the news of a extended deal with USN following which it will supply Phytofare® catechin complex to the respective company and its associates.
The VP of Sales and Marketing for Plandai said that USN acknowledges the many benefits of phyto-availability™. In fact the group is keen to use the Phytofare component in their absolute best quality products sold to clients. Phytofare® is believed to be a magical component that supplies active ingredients to the blood stream.
The VP added that they are delighted with the extensive use of Phytofare by USN in its products meant for various target markets including South Africa, Europe and Australian continent. This deal extension is encouraging for Plandai in terms of revenue and standing in the market.
Cannabis Science Inc (OTCMKTS:CBIS) Recruits New CMO
Cannabis Science Inc (OTCMKTS:CBIS) reported that it engaged well-known epidemiologist, public health physician and also a scholar Allen A. Herman, M.B., Ch.B., Ph.D. as the CMO of company. Dr. Herman is also a part of Cannabis Scientific Advisory Board.
Cannabis Science stated that Dr. Herman was a program director as well as project officer at the NIH. For his accomplishments in child and maternal health, he was awarded with the NIH’s Award of Merit. Dr. developed the platform for a infant mortality reduction plan in the U.S. and was the co-director of the projects seen together by the CDC and NIH.
Metabolix, Inc. (NASDAQ:MBLX) Consolidates
In last trading session, the stock price of Metabolix, Inc. (NASDAQ:MBLX) consolidated and closed flat at $1.97. The company recently reported the establishment of a ‘Yield10 Bioscience’ team to boost the innovations in segment of crop science.